Pleiotropicity of immunomodulating effects of synthetic thymic hexapeptide in chronic infectious and inflammatory diseases of the genital tract in immunocompromized women

Cover Page

Cite item

Full Text

Abstract

A reason for a protracted course and frequent recurrence of pelvic inflammatory diseases (PID) is dysfunction of the immune system, which dictates the need of effective immunotherapeutic approaches. Objective: to clarify the features of immune system functioning, the interferon system, the profile of cytokines during the period of exacerbation of PID in women; to develop targeted immunotherapy using hexapeptide with assessment of its effectiveness. The studied immunocompromised women 20-40 years old with exacerbation of PID were divided into study groups (SG): SG1 (n = 22), SG2 (n = 70) before treatment; SG1a, SG1 receiving standard therapy; SG2a, SG2, receiving standard therapy and hexapeptide (HP, Imunofan®). The parameters of cellular and humoral immunity, levels of serum interferons, cytokines were determined. During exacerbation of PID, a decrease in IFNα was in both groups and IFNγ, more pronounced in SG1. In SG1, the levels of IL-6, TNFα were increased, the level of IL-8 was decreased. In SG2, the level of IL-6 was increased. An increase in IL-4, IL-10 was noted in both groups. Against the background of IFNα, IFNγ deficiency and cytokine imbalance, a significant decrease in T lymphocytes, T helper cells, B lymphocytes was observed in both study groups. After standard treatment, there was no recovery of IFNα, IFNγ. Only TNFα decreased, the levels of IL-1β, IL-6 were increased at the end of treatment, there was no increase in IL-4, IL-10 and restoration of cellular and humoral immunity. It leads to maintaining chronic inflammation and exacerbation of PID within 3 months after treatment. After immunotherapy including fHP, IFNα was restored in 50% cases. There was a decrease in IL-1β, TNFα without significant changes in the levels of IL-8, IL-18. Resolution of inflammation was accompanied by an increase in IL-10. The modulating effect of fHP on interferons and cytokines contributed to the restoration of T cell and humoral immunity, which is related to the onset of clinical remission of PID at an earlier time and an increase in the duration of the inter-relapse period. The positive effectiveness of immunotherapy with Imunofan® is due to its pleiotropic effects, which provides significant advantages compared to the use of standard therapy only.

About the authors

I. V. Nesterova

Kuban State Medical University; P. Lumumba Peoples’ Friendship University of Russia

Author for correspondence.
Email: inesterova1@yandex.ru

PhD, MD (Medicine), Professor, Chief Research Associate, Department of Clinical and Experimental Immunology and Molecular Biology, Central Scientific Research Laboratory; Professor, Department of Clinical Immunology, Allergology and Adaptology Faculty of Continuing Medical Education of the Medical Institute

Russian Federation, Krasnodar; Moscow

S. V. Kovaleva

Kuban State Medical University

Email: inesterova1@yandex.ru

PhD, MD (Medicine), Associate Professor, Senior Research Associate of the Department of Clinical and Experimental Immunology and Molecular Biology, Central Scientific Research Laboratory, Associate Professor of the Department of Clinical Immunology, Allergology and Laboratory Diagnostics of FAT and PRS

Russian Federation, Krasnodar

S. N. Pikturno

Kuban State Medical University

Email: inesterova1@yandex.ru

Postgraduate Student, Department of Clinical Immunology, Allergology and Laboratory Diagnostics of FAT and PRS

Russian Federation, Krasnodar

А. M. Chulkova

Kuban State Medical University

Email: inesterova1@yandex.ru

PhD (Medicine), Head, Day Hospital Clinic

Russian Federation, Krasnodar

N. N. Kuranova

Kuban State Medical University

Email: inesterova1@yandex.ru

Doctor of the Consulting and Diagnostic Department Clinic

Russian Federation, Krasnodar

A. I. Pirogova

Kuban State Medical University

Email: inesterova1@yandex.ru

Resident, Department of Clinical Immunology, Allergology and Laboratory Diagnostics of FAT and PRS

Russian Federation, Krasnodar

E. A. Poezzhaev

Kuban State Medical University

Email: inesterova1@yandex.ru

6th-Year Student of Pediatric Faculty

Russian Federation, Krasnodar

References

  1. Блохин Б.М., Прохорова А.Д., Суюндукова А.С. Актуальные вопросы интерферонотерапии // Терапия, 2018. № 7-8 (25-26). С. 125-132. [Blokhin B.M., Prokhorova A.D., Suyundukova A.S. Topical issues of interferon therapy. Terapiya = Therapy, 2018, no. 7-8 (25-26), pp. 125-132. (In Russ.)]
  2. Зиганшин А.М., Мудров В.А. Оптимизация комплексной терапии воспалительных заболеваний органов малого таза у женщин // Гинекология, 2019. № 21 (3). С. 30-34. [Ziganshin A.M., Mudrov V.A. Optimization of complex therapy of inflammatory diseases of women pelvic organs. Ginekologiya = Ginecology, 2019, no. 21 (3), pp. 30-34. (In Russ.)]
  3. Ковалева С.В., Нестерова И.В., Пиктурно С.Н., Чудилова Г.А., Ломтатидзе Л.В., Тетерин Ю.В., Пирогова А.И., Просолупова Н.С., Чулкова А.М. Эффективность иммуномодулирующей терапии синтетическим аналогом активного центра гормона тимуса тимопоэтина в комплексном лечении иммунокомпрометированных женщин с хроническими инфекционно-воспалительными заболеваниями органов малого таза // Российский иммунологический журнал, 2023. Т. 26, № 3. С. 287-294. [Kovaleva S.V., Nesterova I.V., Pikturno S.N., Chudilova G.A., Lomtatidze L.V., Teterin Yu.V., Pirogova A.I., Prosolupova N.S., Chulkova А.М. Effectiveness of immunomodulatory therapy with a synthetic analogue of the active center of thymopoietin in the complex treatment of immunocompromised women with chronic infectious and inflammatory diseases of the pelvic organs. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2023, Vol. 26, no. 3, pp. 287-294. (In Russ.)] doi: 10.46235/1028-7221-10011-EO.
  4. Маркова Т.П., Чувиров Д.Г. Имунофан в комплексном лечении детей c повторными респираторными заболеваниями и микоплазменной инфекцией // Эффективная фармакотерапия, 2022. Т. 18, № 12. С. 12-18. [Markova T.P., Chuvirov D.G. Imunofan in the complex treatment of children with recurrent respiratory diseases and mycoplasma infection. Effektivnaya farmakoterapiya = Effective Pharmacotherapy, 2022, Vol. 18, no. 12, pp. 12-18. (In Russ.)]
  5. Нестерова И.В., Ковалева С.В., Чудилова Г.А., Пиктурно С.Н., Ломтатидзе Л.В., Чулкова А.М., Просолупова Н.С., Тетерин Ю.В. Позитивная клинико-иммунологическая эффективность препарата Имунофан® в комплексном лечении иммунокомпрометированных женщин с хроническими инфекционно-воспалительными заболеваниями генитального тракта // Эффективная фармакотерапия, 2023. Т. 19, № 26. С. 8-14. [Nesterova I.V., Kovaleva S.V., Chudilova G.A., Pikturno S.N., Lomtatidze L.V., Chulkova A.M., Prosolupova N.S., Teterin Yu.V. Positive clinical and immunological efficacy of the drug Imunofan® in the complex treatment of immunocompromised women with chronic infectious and inflammatory diseases of the genital tract. Effektivnaya farmakoterapiya = Effective Pharmacotherapy, 2023, Vol. 19, no, 26, pp. 8-14,
  6. Нестерова И.В. Таргетная иммунотерапия при вторичных иммунодефицитах с инфекционным синдромом // Российский иммунологический журнал, 2019. Т. 13, № 4 (22). С. 1512-1516. [Nesterova I.V. Targeted immunotherapy for secondary immunodeficiency with infectious syndrome. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2019, Vol. 13, no. 4, pp. 1512-1516. (In Russ.)] doi: 10.31857/S102872210007074-6.
  7. Нестерова И.В., Татаурщикова Н.С. Перспективы развития адаптивной медицинской иммунологии // Медицинская иммунология, 2023. Т. 25, № 6. С. 1277-1288. [Nesterova I.V., Tataurschikova N.S. Prospects for the development of adaptive medical immunology. Meditsinskaya immunologiya = Medical Immunology (Russia), 2023, Vol. 25, no. 6, pp. 1277-1288. (In Russ.)] doi: 10.15789/1563-0625-PFT-2890
  8. Нуралиев Н., Мустафаева Ф. Оценка иммунного статуса и эффективности иммуннокоррекции воспалительных заболеваний органов малого таза у женщин // Вестник врача, Т. 1, № 3. С. 141-148. [Nuraliev N., Mustafayeva F. Assessment of the immune status and effectiveness of immunocorrection of inflammatory diseases of the pelvic organs in women. Vestnik vracha = Bulletin of the Doctor, 2020, Vol. 1, no. 3, pp. 141-148. (In Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure 1. Indicators of the cellular and humoral components of the immune system of immunocompromised women during the period of exacerbation of PID during treatment: A, against the background of a course of standard therapy; B, against the background of complex therapy, including traditional therapy and immunotherapy with a pharmaceutical drug based on GP

Download (204KB)

Copyright (c) 2024 Nesterova I.V., Kovaleva S.V., Pikturno S.N., Chulkova А.M., Kuranova N.N., Pirogova A.I., Poezzhaev E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies